Matrix metalloproteinases 2, 7, and 9 and tissue inhibitor of metalloproteinases-1 in tumors and serum of patients with ovarian neoplasms

Bulletin of Experimental Biology and Medicine

Volumn 149, Issue 5, 2010, Pages 628-631

  Gershtein, E S ^a   Levkina, N V ^a   Digayeva, M A ^a   Laktionov, K P ^a   Tereshkina, I V ^a   Kushlinsky, N E ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

Matrix metalloproteinases 2, 7, and 9, and tissue inhibitor of metalloproteinases 1; Ovarian tumors

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; GELATINASE A; GELATINASE B; MATRILYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR MARKER;

ADULT; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; OVARY CANCER; OVARY TUMOR; PROTEIN BLOOD LEVEL; TISSUE LEVEL; TUMOR VOLUME; ULTRASOUND;

ADULT; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; OVARIAN NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 79951667299     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-010-1010-4     Document Type: Article

References (15)

1. E. C. Gershtein, E. A. Korotkova, A. M. Shcherbakov, et al., Byull. Eksp. Biol. Med., 143, No. 3, 438-441 (2007).
2. K. Q. Cai, W.L. Yang, C. D. Capo-Chichi, et al., Mol. Carcinog., 46, No. 2, 130-143 (2007).
3. A. Demeter, I. Sziller, Z. Csapo, et al., Anticancer Res., 25, No. 4, 2885-2889 (2005).
4. E. I. Deryugina and J. P. Quigley, Cancer Met. Rev., 25, No. 1, 9-34 (2006).
5. A. A. Kamat, M. Fletcher, L. M. Gruman, et al., Clin. Cancer Res., 12, No. 6, 1707-1714 (2006).
6. M. Maatta, A. Talvensaari-Mattila, T. Turpeenniemi-Hujanen, and M. Santala, Anticancer Res., 27, No. 4C, 2753-2758 (2007).
7. S. Ozalp, H. M. Tanir, O. T. Yalcin, et al., Eur. J. Gynaecol. Oncol., 24, No. 5, 417-420 (2003).
8. M. Perigny, I. Bairati, I. Harvey, et al., Am. J. Clin. Pathol., 129, No. 2, 226-231 (2008).
9. N. Ramnath and P. J. Creaven, Curr. Oncol. Rep., 6, No. 2, 96-102 (2004).
10. M. Rauvala, U. Puistola, and T. Turpeenniemi-Hujanen, Gynecol. Oncol., 99, No. 3, 656-663 (2005).
11. M. Rauvala, T. Turpeenniemi-Hujanen, and U. Puistola, Anticancer Res., 26, No. 6C, 4779-4784 (2006).
12. S. Sillanpaa, M. Anttila, K. Suhonen et al., Tumour Biol., 28, No. 5, 280-289 (2007).
13. S. Sillanpaa, M. Anttila, K. Voutilainen, et al., Gynecol. Oncol., 104, No. 2, 296-303 (2007).
14. S. M. Sillanpaa, M. A. Anttila, K. A. Voutilainen, et al., Int. J. Cancer, 119, No. 8, 1792-1799 (2006).
15. K. Zaman, R. Driscoll, D. Hahn, et al., Int. J. Cancer Ibid, 118, No. 3, 755-764 (2006).